AGTC to Present at Upcoming Scientific Conferences
October 04 2016 - 7:00AM
Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical
stage biotechnology company developing adeno-associated virus
(AAV)-based gene therapies for the treatment of rare eye diseases,
today announced participation in three upcoming scientific
conferences.
- Cell & Gene Meeting on the Mesa — La Jolla, Calif.
(October 5-7, 2016) Sue Washer, AGTC President and CEO,
will be delivering a company presentation on October 5, 2016 at
2:45 p.m. PDT and will also participate in a panel discussion
titled “Gene Therapy: Commercializing a Therapeutic Product” on
October 6, 2016 at 3:15 p.m. PDT.
- BioFlorida Annual Conference— Jacksonville, Fla.
(October 9-11, 2016)Sue Washer will take part in a
discussion titled “Florida Areas of Strength: Cell Therapy and
Regenerative Medicine” at 11:40 a.m. EDT and will be moderating the
conference’s CEO Panel at 4:55 p.m. EDT on October 10, 2016.
- OIS@AAO — Chicago, Ill. (October 13, 2016)Sue
Washer will participate in the Gene & Stem Cell Therapies
Breakfast Breakout Session beginning at 7:30 a.m. CDT. She will
present a brief corporate overview at 11:07 a.m. CDT as part of the
conference’s Posterior Segment Company Showcase.
About AGTC
AGTC is a clinical-stage biotechnology company
that uses its proprietary gene therapy platform to develop products
designed to transform the lives of patients with severe diseases,
with an initial focus in ophthalmology. AGTC's lead product
candidates are designed to treat inherited orphan diseases of the
eye, caused by mutations in single genes that significantly affect
visual function and currently lack effective medical
treatments.
AGTC's product pipeline includes six named
ophthalmology development programs across five targets (X-linked
retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP),
achromatopsia, wet age-related macular degeneration and blue cone
monochromacy), two non-ophthalmology programs (alpha-1 antitrypsin
deficiency and adrenoleukodystrophy) and AGTC is continuing to
develop early research studies in additional indications. The
company is also exploring genetic defects in cells in the inner ear
that lead to deafness and expects to advance several product
candidates into development within the next few years. AGTC employs
a highly targeted approach to selecting and designing its product
candidates, choosing to develop therapies for indications having
high unmet medical need, clinical feasibility and commercial
potential. AGTC has a significant intellectual property portfolio
and extensive expertise in the design of gene therapy products
including capsids, promoters and expression cassettes, as well as,
expertise in the formulation, manufacture and physical delivery of
gene therapy products.
IR/PR CONTACTS:
David Carey (IR) or Danielle Lewis (PR)
Lazar Partners Ltd.
T: (212) 867-1768 or (212) 843-0211
dcarey@lazarpartners.com or dlewis@lazarpartners.com
CORPORATE CONTACTS:
Larry Bullock
Chief Financial Officer
Applied Genetic Technologies Corporation
T: (386) 462-2204
lbullock@agtc.com
Stephen Potter
Chief Business Officer
Applied Genetic Technologies Corporation
T: (617) 413-2754
spotter@agtc.com
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Apr 2023 to Apr 2024